Nicole A. Turgeon

TL;DR: The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.

TL;DR: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs and should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.

TL;DR: Although KAS has arguably increased fairness in allocation, the potential costs of broadening access must be considered, as delayed graft function rates have increased, but 6‐month graft survival rates have not changed significantly.

TL;DR: The results demonstrate the feasibility of implementing a harmonized process at multiple facilities for the manufacture of a complex cellular product and the quality systems and regulatory and operational strategies developed by the CIT Consortium yielded product lots that met the prespecified characteristics of safety, purity, potency, and identity.